Deutsche Bank lowered the firm’s price target on Genmab (GMAB) to DKK 2,250 from DKK 2,500 and keeps a Buy rating on the shares.

Genmab A/S and/or its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo®; HuMax®; DuoBody®; HexaBody ...

Analysts' ratings for Genmab GMAB over the last quarter vary from bullish to bearish, as provided by 10 analysts. The following table provides a quick overview of their recent ratings ...

Genmab is an international biotechnology company with a core purpose of guiding its unstoppable team to strive toward improving the lives of patients with innovative and differentiated antibody ...

It has been roughly eight months since my last Genmab (GMAB) article, where I highlighted the company's robust pipeline progress, strategic partnerships, and a strong 2023 performance, led by ...

An influx of late-phase programs has prompted Genmab to reassess its bets. The biotech is axing three early-stage clinical programs to accelerate investment in its recently expanded phase 3 pipeline.

Management revised its revenue guidance upwards while lowering its expense forecast. Genmab reported impressive earnings with significant revenue growth driven by its key products, despite rising ...

COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB): More than 20 abstracts, including four oral presentations, with new clinical data across lines of therapy and subgroups of non ...

Genmab GMAB will release its quarterly earnings report on Wednesday, 2024-11-06. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Genmab to report an earnings ...

November 6, 2024 Copenhagen, Denmark; Interim Report for the First Nine Months Ended September 30, 2024HighlightsEuropean Commission (EC) granted ...

“The third quarter of 2024 presented Genmab with additional opportunities to progress towards our goal of fundamentally transforming the lives of people with cancer and other serious disease ...